IN2015DN01223A - - Google Patents
Info
- Publication number
- IN2015DN01223A IN2015DN01223A IN1223DEN2015A IN2015DN01223A IN 2015DN01223 A IN2015DN01223 A IN 2015DN01223A IN 1223DEN2015 A IN1223DEN2015 A IN 1223DEN2015A IN 2015DN01223 A IN2015DN01223 A IN 2015DN01223A
- Authority
- IN
- India
- Prior art keywords
- compounds
- cancer
- compositions
- treatment
- quinone
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000004053 quinones Chemical class 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Quinone Compounds and Their Uses for the Treatment of Cancer Quinone compounds having useful therapeutic activity such as anticancer activity and compositions comprising such compounds are described. The use of such compounds and compositions in the treatment of cancer is also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1213486.2A GB201213486D0 (en) | 2012-07-30 | 2012-07-30 | Quinone compounds and their uses for the treatment of cancer |
| PCT/EP2013/065968 WO2014020012A1 (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01223A true IN2015DN01223A (en) | 2015-06-26 |
Family
ID=46881339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1223DEN2015 IN2015DN01223A (en) | 2012-07-30 | 2013-07-30 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9266829B2 (en) |
| EP (1) | EP2882743B1 (en) |
| JP (1) | JP6317742B2 (en) |
| KR (1) | KR102142164B1 (en) |
| CN (1) | CN104583200B (en) |
| AU (1) | AU2013298653B2 (en) |
| BR (1) | BR112015001837B1 (en) |
| CA (1) | CA2880021C (en) |
| DK (1) | DK2882743T3 (en) |
| ES (1) | ES2662917T3 (en) |
| GB (2) | GB201213486D0 (en) |
| HK (1) | HK1209111A1 (en) |
| IN (1) | IN2015DN01223A (en) |
| MX (1) | MX361650B (en) |
| NO (1) | NO2882743T3 (en) |
| RU (1) | RU2688675C2 (en) |
| WO (1) | WO2014020012A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156744A (en) * | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| EP1784172A4 (en) * | 2004-06-21 | 2007-12-19 | Hutchison Medipharma Entpr Ltd | Cancer chemotherapy |
| EP2134322B1 (en) * | 2007-03-13 | 2019-02-20 | Spectrum Pharmaceuticals, Inc. | Intravesical apaziquone administration following transurethral resection for treating bladder cancer |
-
2012
- 2012-07-30 GB GBGB1213486.2A patent/GB201213486D0/en not_active Ceased
-
2013
- 2013-07-30 GB GB1422799.5A patent/GB2519004B/en not_active Expired - Fee Related
- 2013-07-30 CN CN201380040388.1A patent/CN104583200B/en not_active Expired - Fee Related
- 2013-07-30 MX MX2015000969A patent/MX361650B/en active IP Right Grant
- 2013-07-30 RU RU2015105036A patent/RU2688675C2/en not_active IP Right Cessation
- 2013-07-30 NO NO13742640A patent/NO2882743T3/no unknown
- 2013-07-30 ES ES13742640.9T patent/ES2662917T3/en active Active
- 2013-07-30 DK DK13742640.9T patent/DK2882743T3/en active
- 2013-07-30 IN IN1223DEN2015 patent/IN2015DN01223A/en unknown
- 2013-07-30 JP JP2015524762A patent/JP6317742B2/en not_active Expired - Fee Related
- 2013-07-30 CA CA2880021A patent/CA2880021C/en not_active Expired - Fee Related
- 2013-07-30 KR KR1020157002128A patent/KR102142164B1/en active IP Right Grant
- 2013-07-30 AU AU2013298653A patent/AU2013298653B2/en not_active Ceased
- 2013-07-30 US US14/418,394 patent/US9266829B2/en not_active Expired - Fee Related
- 2013-07-30 WO PCT/EP2013/065968 patent/WO2014020012A1/en active Application Filing
- 2013-07-30 EP EP13742640.9A patent/EP2882743B1/en not_active Not-in-force
- 2013-07-30 BR BR112015001837-8A patent/BR112015001837B1/en not_active IP Right Cessation
-
2015
- 2015-10-06 HK HK15109758.6A patent/HK1209111A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2880021C (en) | 2020-01-14 |
| RU2015105036A (en) | 2016-09-20 |
| HK1209111A1 (en) | 2016-03-24 |
| NO2882743T3 (en) | 2018-05-12 |
| US20150210639A1 (en) | 2015-07-30 |
| WO2014020012A1 (en) | 2014-02-06 |
| BR112015001837A2 (en) | 2017-07-04 |
| KR102142164B1 (en) | 2020-08-06 |
| AU2013298653A1 (en) | 2015-02-19 |
| DK2882743T3 (en) | 2018-03-12 |
| GB2519004A (en) | 2015-04-08 |
| JP6317742B2 (en) | 2018-04-25 |
| CN104583200A (en) | 2015-04-29 |
| MX361650B (en) | 2018-12-13 |
| GB2519004B (en) | 2016-03-30 |
| KR20150036215A (en) | 2015-04-07 |
| JP2015524815A (en) | 2015-08-27 |
| RU2688675C2 (en) | 2019-05-22 |
| ES2662917T3 (en) | 2018-04-10 |
| MX2015000969A (en) | 2015-09-23 |
| BR112015001837B1 (en) | 2021-11-16 |
| EP2882743A1 (en) | 2015-06-17 |
| CA2880021A1 (en) | 2014-02-06 |
| US9266829B2 (en) | 2016-02-23 |
| AU2013298653B2 (en) | 2017-10-19 |
| GB201213486D0 (en) | 2012-09-12 |
| CN104583200B (en) | 2017-07-25 |
| EP2882743B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502809A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2020010535A (en) | Methods of treating cancer. | |
| PH12015501552A1 (en) | Androgen receptor modulator and uses thereof | |
| IN2014MN02069A (en) | ||
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| NZ706738A (en) | Substituted benzene compounds | |
| IN2014MN02049A (en) | ||
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| MX2014008705A (en) | Tricyclic sulfone compounds and methods of making and using same. | |
| MX356755B (en) | Fumigillol type compounds and methods of making and using same. | |
| IN2014MN01945A (en) | ||
| PH12015501302A1 (en) | Compositions comprising vortioxetine and donepezil | |
| MX2015005732A (en) | Tricyclic compounds and methods of making and using same. | |
| IN2014MN01944A (en) | ||
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| IN2015DN01223A (en) |